Stockholm – April 12, 2023 – Inify Laboratories, a company providing fully digitalized laboratory services within prostate cancer diagnostics, presents its Annual Report for the fiscal year ended December 31, 2022.
The annual report is attached to this press release and is also available on the company’s website: www.inify.com.
Printed copies of the report will be distributed upon request sent to e-mail: .
For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: or:
About Inify Laboratories
Inify Laboratories is currently building and establishing an ultramodern laboratory that will provide cancer diagnostics within histopathology. Designed from scratch, it uses a fully digital, standardized and AI-supported workflow to optimize quality and shorten response times, initially within prostate cancer. The first laboratory, located at Campus Solna Sweden, is estimated to start offering services to both public and private healthcare providers before summer 2023.
The company originates from ContextVision, with nearly 40 years of experience within digital imaging for medical applications and became independent through a spin-off in February 2022. The company, based in Sweden, is listed on Euronext Growth Oslo under the ticker INIFY.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.